Section of Clinical Biochemistry, University of Verona, Verona, Italy.
Service of Laboratory Medicine, Pederzoli Hospital, Peschiera del Garda, Italy.
Clin Chem Lab Med. 2021 Apr 12;59(9):1585-1591. doi: 10.1515/cclm-2021-0339. Print 2021 Aug 26.
Since universal vaccination is a pillar against coronavirus disease 2019 (COVID-19), monitoring anti-SARS-CoV-2 neutralizing antibodies is essential for deciphering post-vaccination immune response.
Three healthcare workers received 30 μg BNT162b2 mRNA Covid-19 Pfizer Vaccine, followed by a second identical dose, 21 days afterwards. Venous blood was drawn at baseline and at serial intervals, up to 63 days afterwards, for assessing total immunoglobulins (Ig) anti-RBD (receptor binding domain), anti-S1/S2 and anti-RBD IgG, anti-RBD and anti-N/S1 IgM, and anti-S1 IgA.
All subjects were SARS-CoV-2 seronegative at baseline. Total Ig anti-RBD, anti-S1/S2 and anti-RBD IgG levels increased between 91 and 368 folds until 21 days after the first vaccine dose, then reached a plateau. The levels raised further after the second dose (by ∼30-, ∼8- and ∼8-fold, respectively), peaking at day 35, but then slightly declining and stabilizing ∼50 days after the first vaccine dose. Anti-S1 IgA levels increased between 7 and 11 days after the first dose, slightly declined before the second dose, after which levels augmented by ∼24-fold from baseline. The anti-RBD and anti-N/S1 IgM kinetics were similar to that of anti-S1 IgA, though displaying substantially weaker increases and modest peaks, only 4- to 7-fold higher than baseline. Highly significant inter-correlation was noted between total Ig anti-RBD, anti-S1/S2 and anti-RBD IgG (all r=0.99), whilst other anti-SARS-CoV-2 antibodies displayed lower, though still significant, correlations. Serum spike protein concentration was undetectable at all-time points.
BNT162b2 mRNA vaccination generates a robust humoral immune response, especially involving anti-SARS-Cov-2 IgG and IgA, magnified by the second vaccine dose.
由于普遍接种疫苗是对抗 2019 年冠状病毒病（COVID-19）的一个支柱，因此监测针对 SARS-CoV-2 的中和抗体对于破译疫苗接种后的免疫反应至关重要。
3 名医护人员接受了 30μg 的 BNT162b2 mRNA 辉瑞疫苗，21 天后接种了第二剂相同剂量的疫苗。在基线和随后的连续间隔时间内抽取静脉血，最多 63 天，以评估总免疫球蛋白（Ig）抗 RBD（受体结合域）、抗 S1/S2 和抗 RBD IgG、抗 RBD 和抗 N/S1 IgM，以及抗 S1 IgA。
所有受试者在基线时均为 SARS-CoV-2 血清阴性。总 Ig 抗 RBD、抗 S1/S2 和抗 RBD IgG 水平在第一剂疫苗后 91 至 368 倍之间增加，然后达到稳定水平。第二剂疫苗后水平进一步升高（分别增加约 30 倍、8 倍和 8 倍），在第 35 天达到峰值，但随后略下降并在第一剂疫苗后约 50 天稳定。抗 S1 IgA 水平在第一剂疫苗后 7 至 11 天内升高，在第二剂疫苗前略有下降，之后从基线水平增加约 24 倍。抗 RBD 和抗 N/S1 IgM 动力学与抗 S1 IgA 相似，尽管增加幅度较小且峰值适度，仅比基线高 4 至 7 倍。总 Ig 抗 RBD、抗 S1/S2 和抗 RBD IgG 之间存在高度显著的相互相关性（均 r=0.99），而其他抗 SARS-CoV-2 抗体的相关性虽然较低，但仍然显著。在所有时间点均未检测到血清刺突蛋白浓度。
BNT162b2 mRNA 疫苗接种可产生强大的体液免疫反应，特别是涉及抗 SARS-CoV-2 IgG 和 IgA，第二剂疫苗可进一步增强这种反应。
